

# Retrospective Study on Rapid Glaucoma Screening in a Polyclinic Setup:

ASSESSMENT OF A LARGE COHORT IN A SHORT DURATION

**DR. SRILEKHA PALLAMPARTHY**

MBBS (OSMANIA), M.S OPHTHAL. (JIPMER), FAEH

(GLAUCOMA)

# \* Introduction \*



Glaucoma - foremost cause of irreversible blindness worldwide.<sup>1,2</sup>



Progression - prevented or stabilized when identified early and managed appropriately.<sup>2</sup>



Glaucoma screening can help in detection of the disease early<sup>3</sup>

# \* MC methods<sup>4</sup> \*

FDT- C-  
20-1

Disc  
Photography

Ophthalmoscopy

HFA

OCT

Tonometry

Oculokinetic  
Perimetry

HRT

But no single test fully meets the criteria of an ideal method.<sup>4</sup>

# \* Challenges \*



Lack of equipment such as perimeter and tomography in most of the outpatient clinics



Limited insurance approval for glaucoma screening.




Cost and duration of screenings (mydriasis, field analysis).



Lack of structured screening protocols.

To address these challenges, a **screening method**, alternative to no action, can be adopted to decrease the disease burden

# \* My Research \*



Retrospective Study - Free Glaucoma Screening  
World Glaucoma Week at Apollo Clinic, Dubai



Adapted rapid screening method  
Due to high patient turnout in a short timeframe.



Aimed to swiftly and accurately identify



- Disc suspects
- Ocular hypertensives
- Angle closure cases

# \*Methodology\*

Approval obtained from the Dubai Scientific Research Ethics Committee (DSREC)

## Sample

- Total screened – 793 patients
- Excluded –
  - Under 18
  - Infections
  - Previous diagnosis of glaucoma
- **Final Sample – 761 patients**



# Screening Protocol

1. Visual Acuity


2. NCT



3. Slit-Lamp



4. Optic disc



Assessment using Snellen's chart with a pinhole

# Screening Protocol

1. Visual Acuity

2. NCT

3. Slit-Lamp




4. Optic disc




Non-contact tonometry with the Nidek NT 530





# NCT



## Non-contact tonometry

- It compares favorably with the Goldmann applanation tonometer and serves as a reliable screening tool (Kadu et al., 2018).<sup>5</sup>
- Research indicates that non-ophthalmologists can perform NCT reliably (Niessen et al., 1997; Shields, 1980).<sup>6,7</sup>



# Screening Protocol

1. Visual Acuity



2. NCT

**3 Slit-Lamp**

4. Optic disc



Slit-lamp examination with the Keeler KSL-H. Primarily VH technique

# \* Van Hericks grading \*

## LIMBAL ANTERIOR CHAMBER DEPTH

- Valuable tool, especially in cases of limited access to the most recent technologies (Jindal et al., 2020; Riva et al., 2020).<sup>8,9</sup>
- Provides reasonably accurate angle closure risk assessment and good inter-user reliability. (Friedman et al., 2008)<sup>10</sup>



# Screening Protocol

1. Visual Acuity



2. NCT



3. Slit-Lamp


**4 Optic disc**




Non-mydriatic optic disc  
evaluation using a 90 D lens

# Non-mydriatic Ophthalmoscopy

- If a satisfactory optic disc view can be achieved without dilation, non-mydriatic optic disc evaluation is adequate (O'Brien et al., 2005).<sup>11</sup>
- Moreover, ophthalmoscopy and disc photography have been shown to be superior diagnostic imaging techniques for glaucoma (Spaeth & Reddy, 2014).<sup>12</sup>





# Criteria



## Disc suspect

- CDR of 0.7 or above
- CDR difference of 0.2 between the eyes
- Any CDR where the vertical cup - larger than the horizontal
- CDR of 0.6 with a disparity of 0.1 between the two eyes

## Ocular Hypertension


- IOP >21mmHg, without disc suspect indicators


## Shallow AC

- Van Herrick's grading of 2 or worse




# Results






# Age



n-761




# Gender



n-761

**Above 60**

**5.3%**



**Below 40**

**34.2%**

260

461


40

**40-60**

**60.6%**

**Females**

**14.9%**




113

648

**Males**

**85.2%**







# Health History




n-761



# Family History of Glaucoma




n-761



# \* Ocular Complaints \*


n-724




**27.86% (212 patients)**  
vision-related issues, MC- Refraction

**23.13% (176 patients)**  
ocular surface complaints, MC-  
dry eye

**4.34% (33 patients)**  
Other specific ocular complaints



# Mean



**Visual Acuity:**  
(LogMAR)

OD :  $0.05 \pm 0.18$  (n=761)

OS :  $0.04 \pm 0.15$  (n=761)



**Intraocular Pressure (IOP):**  
(mmHg)

OD :  $14.36 \pm 2.97$  (n=761)

OS :  $14.28 \pm 3.1$  (n=761)



**Cup-to-Disc Ratio (CDR):**

OD :  $0.412 \pm 0.126$  (n=756)

OS :  $0.414 \pm 0.128$  (n=757)

# **Screening Results**

# Glaucoma Screening (147)



Disc Suspects:  
115 (15.11%)



Ocular Hypertensives:  
15 (1.97%)



Shallow Anterior  
Chamber: 17 (2.23%)

# Other ocular conditions

Dry Eyes: 123

Diabetic Retinopathy (DR) Changes: 23  
(20.72% of diabetics)



Diabetic Macular Edema (DME): 5

Early cataract- 31  
Cataract: 19

Additional Conditions: CSCR, Coloboma, Macular Scar, CRVO with Macular Edema, Optic Atrophy, Corneal Scar, Myelinated Nerve Fiber, Chalazion, TON, Pterygium


# \* Risk Factors \*

## Disc Suspect

- >60 years (p-0.025)
- Hypertension (p-0.004)
- Heart disease (p-0.023)
- Family history of glaucoma (p-0.013)
- IOP above 21mmhg (p-0.007)

## Ocular Hypertension

- Diabetes (p-0.005)



# Follow-up



147 patients ➤ 19 patients

## Comprehensive Glaucoma evaluation

## 19 CASES

9

Primary Open-Angle Glaucoma (POAG)

4

Normal-Tension Glaucoma (NTG)

2

Physiological Cupping

1

Ocular Hypertensive

1

Primary Angle Closure

1

Steroid-Induced Glaucoma

1

Posner-Schlossmann Syndrome



# \* Limitations \*



The primary limitation -low follow up rate after the free screening


## MC reasons

- Cost associated with subsequent investigations.
- Insurance constraints for follow-up visits.
- Tendency to seek evaluations in their home countries
- Defer them to a future date.

Although limited follow-up rates could impact confirming this screening method's efficiency, it is a valuable tool for early glaucoma detection when utilized by a trained ophthalmologist.



# Benefits



## EARLY DETECTION

Potential for significant early glaucoma detection, thus reducing the burden of advanced cases and blindness.


## SPEEDY POPULATION ANALYSIS

Can screen a large population in a short time.

## BENEFITS FOR HEALTHCARE

Cost-saving implications and improved healthcare efficiency.

# Glaucoma Screening Integration



## INTEGRATION INTO EVERYDAY PRACTICE:

- Integrate into passive screening regardless of risk factors.



## RESOURCE-EFFICIENT SCREENING PROGRAMS:

- Integrate into screening programs with limited resources and time

# \* Conclusion \*



## **STUDY INSIGHTS:**

The study sheds light on rapid glaucoma screening outcomes, within the context of Dubai's polyclinic setup



## **KEY FINDINGS:**

Risk factors include age (60+), hypertension, heart disease, diabetes, family history, and elevated IOP.



## **RAPID SCREENING:**

Early detection within a limited timeframe.



## **FUTURE PROSPECTS:**


Integrating these methods into everyday practice can enhance early detection, potentially reducing overall glaucoma prevalence.

# Future Directions



## OVERCOMING LIMITATIONS:

- Enhancing follow-up and addressing insurance and cost-related challenges.



## ADVANCEMENTS IN RESEARCH:

- Pursuing more effective glaucoma screening methods.
- Refining and validating these approaches.

# References

1. Sun Y, Chen A, Zou M, et al Time trends, associations and prevalence of blindness and vision loss due to glaucoma: an analysis of observational data from the Global Burden of Disease Study 2017BMJ Open 2022;12:e053805. doi: 10.1136/bmjopen-2021-053805
2. Senjam SS. Glaucoma blindness-A rapidly emerging non-communicable ocular disease in India: Addressing the issue with advocacy. J Family Med Prim Care. 2020 May 31;9(5):2200-2206. doi: 10.4103/jfmprc.jfmprc\_111\_20. PMID: 32754474; PMCID: PMC7380776.
3. Song, Y., Kim, Y., Park, K., Kim, Y., Choi, H., & Jeoung, J. (2019). Comparison of glaucoma patients referred by glaucoma screening versus referral from primary eye clinic. PLoS ONE, 14. <https://doi.org/10.1371/journal.pone.0210582>.
4. Momont AC, Mills RP. Glaucoma screening: current perspectives and future directions. Semin Ophthalmol. 2013 May;28(3):185-90. doi: 10.3109/08820538.2013.771200. PMID: 23697622.
5. Kadu, S., Jaiswal, H., Giri, N., & Ingle, S. (2018). Non contact tonometer & applanation tonometer as a screening tool for glaucoma in general population. International journal of biomedical research, 9, 214-220.
6. Niessen, A.G.J.E., Langerhorst, C.T., Geijssen, H.C. et al. Design of low cost glaucoma screening. Doc Ophthalmol 93, 293–315 (1997). <https://doi.org/10.1007/BF02569068>
7. Shields MB. The non-contact tonometer. Its value and limitations. Surv Ophthalmol. 1980 Jan-Feb;24(4):211-9. doi: 10.1016/0039-6257(80)90042-9. PMID: 6987761.
8. Jindal A, Ctori I, Virgili G, Lucenteforte E, Lawrenson JG. Non-contact tests for identifying people at risk of primary angle closure glaucoma. Cochrane Database Syst Rev. 2020 May 28;5(5):CD012947. doi: 10.1002/14651858.CD012947.pub2. PMID: 32468576; PMCID: PMC7390269.
9. Riva I, Micheletti E, Oddone F, Bruttini C, Montescani S, De Angelis G, Rovati L, Weinreb RN, Quaranta L. Anterior Chamber Angle Assessment Techniques: A Review. J Clin Med. 2020 Nov 25;9(12):3814. doi: 10.3390/jcm9123814. PMID: 33255754; PMCID: PMC7759936.
10. Friedman, D. S., & He, M. (2008). Anterior Chamber Angle Assessment Techniques. Survey of Ophthalmology, 53(3), 250–273. doi:10.1016/j.survophthal.2007.10.012 10.1016/j.survophthal.2007.10.012
11. O'Brien, P., Bogdan, A., Fitzpatrick, P. et al. The influence of pharmacological mydriasis on biomicroscopic evaluation of the glaucomatous optic nerve head. Eye 19, 1194–1199 (2005). <https://doi.org/10.1038/sj.eye.6701734>
12. Spaeth, G., & Reddy, S. (2014). Imaging of the optic disk in caring for patients with glaucoma: ophthalmoscopy and photography remain the gold standard.. Survey of ophthalmology, 59 4, 454-8. <https://doi.org/10.1016/j.survophthal.2013.10.004>.



*Thank  
You*

